U.S. License Holder:
Date of License:
FABRAZYME (agalsidase beta) is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Japan
Agalsidase Beta BS (JCR Pharmaceuticals) (November-2018)
U.S. Patent LitigationsPACER
U.S. Patent Nos.
7,011,831 (Recombinant Alpha-Galactosidase A Therapy for Fabry Disease)